selected publications
- Autologous stem cell transplantation for the treatment of MGRS (monoclonal gammopathy of renal significance): experience from the University of Calgary. Leukemia & lymphoma. 2025 Academic Article GET IT
- Artificial intelligence-driven longitudinal quantification of technetium pyrophosphate uptake in cardiac amyloidosis: Correlation with multimodality imaging and outcomes. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology. 2025 Academic Article GET IT
- Clinical outcomes and healthcare resource use in triple-class exposed patients with relapsed/refractory multiple myeloma. Future oncology (London, England). 2025 Academic Article GET IT
- Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database. Clinical lymphoma, myeloma & leukemia. 2025 Academic Article GET IT
- Salvage Autologous Stem Cell Transplantation Outcomes and The Use of Maintenance in Relapsed Multiple Myeloma: Real world evidence from the Canadian Myeloma Research Group Database. Clinical lymphoma, myeloma & leukemia. 2025 Academic Article GET IT
- Incidence and prevalence of clinically detected smoldering multiple myeloma within the general population: a retrospective observational cohort study. Blood cancer journal. 2025 Letter GET IT
- Case report of isolated aortic valve AL-amyloidosis following aortic valve replacement. 2025 GET IT
- BCMA CAR-T: From Multiple Myeloma to Light-Chain Amyloidosis. Current oncology (Toronto, Ont.). 2025 Review GET IT
- Clinical Outcomes for Multiple Myeloma Patients With Prior Exposure to a Combination of a Proteasome Inhibitor and an Immunomodulatory Agent in Alberta, Canada. Clinical lymphoma, myeloma & leukemia. 2025 Academic Article GET IT
- Longitudinal Changes in Multiple Cardiac Biomarkers in Transthyretin Amyloidosis Cardiomyopathy Patients Treated Vs Untreated with Tafamidis. CJC open. 2025 Academic Article GET IT
- Role of a Multidisciplinary Program (Amyloidosis Program of Calgary) on Recognition and Intervention for AL and ATTR Amyloidosis. Clinical lymphoma, myeloma & leukemia. 2025 Academic Article GET IT
-
Treatment Patterns and Outcomes of Multiple Myeloma Patients Undergoing Second-Line Therapy: A Canadian Myeloma Research Group (CMRG) Analysis.
Clinical lymphoma, myeloma & leukemia.
2025
Academic Article
GET IT
Times cited: 1 -
Clinical and Pathological Characteristics of Non-AL Amyloidosis MGRS: A Single-Center Experience Over 10 Years.
Canadian journal of kidney health and disease.
2025
Academic Article
GET IT
Times cited: 1 -
Prevalence and Significance of Incidental PET/CT Findings of Cancer Detected in Patients Evaluated for Their Primary Hematologic Malignancy: A Systematic Review.
Current oncology (Toronto, Ont.).
2024
Academic Article
GET IT
Times cited: 1 - Doxycycline Plus Bortezomib-Containing Regimens for the Treatment of Light-Chain Amyloidosis in the Frontline Setting: Experience from the Amyloidosis Program of Calgary. Current oncology (Toronto, Ont.). 2024 Academic Article GET IT
-
Baseline Predictors of Adverse Outcomes for Transthyretin Amyloidosis Cardiomyopathy Patients Treated and Untreated with Tafamidis: A Canadian Referral Center Experience.
Journal of clinical medicine.
2024
Academic Article
GET IT
Times cited: 2 -
Factors Influencing Clinical Initiation of Tafamidis Therapy for Transthyretin Amyloidosis Cardiomyopathy: A Canadian Referral Center Experience.
The Canadian journal of cardiology.
2024
Letter
GET IT
Times cited: 2 -
Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group Database.
Transplantation and cellular therapy.
2024
Academic Article
GET IT
Times cited: 5 - Long-term follow-up of outcomes including progression-free survival 2 in patients with transplant-ineligible multiple myeloma in the real-world practice: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) database. EJHaem. 2024 Academic Article GET IT
-
Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database.
Blood cancer journal.
2023
Academic Article
GET IT
Times cited: 8 - Daratumumab for the treatment of relapsed/refractory AL amyloidosis: experience from the amyloidosis Program of Calgary (APC). Leukemia & lymphoma. 2023 Academic Article GET IT
-
Long-term survivorship care after CAR-T cell therapy.
European journal of haematology.
2023
Review
GET IT
Times cited: 20 -
Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database.
Blood cancer journal.
2023
Academic Article
GET IT
Times cited: 15 -
Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis.
2023
GET IT
Times cited: 1 -
Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis.
European journal of haematology.
2023
Academic Article
GET IT
Times cited: 2 -
Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis.
Blood cancer journal.
2023
Academic Article
GET IT
Times cited: 15 -
Effect of the Presence of t(11;14) for Patients With AL Amyloidosis Treated With Bortezomib-Containing Regimens: Experience From the Amyloidosis Program of Calgary.
Clinical lymphoma, myeloma & leukemia.
2023
Letter
GET IT
Times cited: 3 -
Corticosteroids as graft-versus-host disease prophylaxis for allogeneic hematopoietic cell transplant recipients with calcineurin inhibitor intolerance.
Cytotherapy.
2023
Academic Article
GET IT
Times cited: 1 -
Diagnostic accuracy of bone scintigraphy imaging for transthyretin cardiac amyloidosis: systematic review and meta-analysis.
Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.
2023
Review
GET IT
Times cited: 21 -
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2023
Academic Article
GET IT
Times cited: 25 -
A Comprehensive Multidisciplinary Diagnostic Algorithm for the Early and Efficient Detection of Amyloidosis.
Clinical lymphoma, myeloma & leukemia.
2022
Academic Article
GET IT
Times cited: 6 -
Monoclonal Gammopathy of Undetermined Significance in Patients With Transthyretin Amyloidosis (ATTR): Analysis Using the iStopMM Criteria.
Clinical lymphoma, myeloma & leukemia.
2022
Academic Article
GET IT
Times cited: 6 - Validation of an administrative coding algorithm for the identification of individuals with amyloid light chain amyloidosis using administrative data. Leukemia & lymphoma. 2022 Letter GET IT
-
Real-world Outcomes With Cumulative Bortezomib Dose and Efficacy in the Treatment of Transplant-ineligible Multiple Myeloma With Cyclophosphamide, Bortezomib, and Dexamethasone.
Clinical lymphoma, myeloma & leukemia.
2022
Academic Article
GET IT
Times cited: 2 -
Real-world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database.
Cancer medicine.
2022
Academic Article
GET IT
Times cited: 3 - Understanding real-world treatment patterns and clinical outcomes in AL amyloidosis patients diagnosed in Canada: A population-based cohort study. EJHaem. 2022 Academic Article GET IT
-
Incomplete chimerism following myeloablative and anti-thymocyte globulin-conditioned hematopoietic cell transplantation is a risk factor for relapse and chronic graft-versus-host disease.
Cytotherapy.
2022
Academic Article
GET IT
Times cited: 4 - Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database. EJHaem. 2022 Academic Article GET IT
-
Amyloidosis and COVID-19: experience from an amyloid program in Canada.
Annals of hematology.
2022
Academic Article
GET IT
Times cited: 16 -
Real-world treatment patterns for patients with newly diagnosed multiple myeloma in Alberta, Canada.
Leukemia & lymphoma.
2022
Academic Article
GET IT
Times cited: 3 -
Amyloidosis Tissue Confirmation for Tafamidis Eligibility Using Transverse Carpal Ligament and Tenosynovium Biopsy.
The Canadian journal of cardiology.
2022
Academic Article
GET IT
Times cited: 4 -
Toward optimization of cyclosporine concentration target to prevent acute graft-versus-host disease following myeloablative allogeneic stem cell transplant.
Clinical transplantation.
2022
Academic Article
GET IT
Times cited: 5 -
Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database.
British journal of haematology.
2022
Academic Article
GET IT
Times cited: 8 -
Suboptimal response for AL amyloidosis: is it time for early switch? Experience from a single amyloid program.
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
2022
Letter
GET IT
Times cited: 1 -
Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group Database.
Clinical lymphoma, myeloma & leukemia.
2022
Academic Article
GET IT
Times cited: 8 -
Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database.
Current oncology (Toronto, Ont.).
2022
Academic Article
GET IT
Times cited: 3 -
Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis.
Frontiers in oncology.
2022
Academic Article
GET IT
Times cited: 7 -
Impact of COVID-19 on the Diagnosis and Management of Multiple Myeloma: Experience from a Canadian Center.
Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.
2022
Academic Article
GET IT
Times cited: 1 -
Quantitative technetium pyrophosphate and cardiovascular magnetic resonance in patients with suspected cardiac amyloidosis.
Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.
2021
Academic Article
GET IT
Times cited: 17 -
Risk Factors for the Incidence of and the Mortality due to Post-Transplant Lymphoproliferative Disorder after Hematopoietic Cell Transplantation.
Transplantation and cellular therapy.
2021
Academic Article
GET IT
Times cited: 21 - Excess of deaths for patients with plasma cell proliferative disorders as a result of the COVID-19 pandemic. Leukemia & lymphoma. 2021 Letter GET IT
-
N-Terminal pro-brain natriuretic peptide (NTproBNP) in patients with symptomatic multiple myeloma: report from a single institution.
Annals of hematology.
2021
Academic Article
GET IT
Times cited: 8 -
Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada.
European journal of haematology.
2021
Academic Article
GET IT
Times cited: 5 -
Treatment response measurements and survival outcomes in a cohort of newly diagnosed AL amyloidosis.
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
2021
Academic Article
GET IT
Times cited: 2 -
Monoclonal Gammopathy of Undetermined Significance Clinic during the Coronavirus Disease-19 Pandemic: Caring for the Vulnerable in an Academic Medical Center.
Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.
2021
Academic Article
GET IT
Times cited: 3 -
The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database.
Haematologica.
2021
Letter
GET IT
Times cited: 10 -
Cyclophosphamide, Bortezomib and Methylprednisolone (CyBorMe) for the Treatment of AL Amyloidosis: Initial Experience From a Single Center.
Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion.
2021
Academic Article
GET IT
Times cited: 1 -
The impact of lenalidomide maintenance on second-line chemotherapy in transplant eligible patients with multiple myeloma.
European journal of haematology.
2021
Academic Article
GET IT
Times cited: 1 -
Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group database.
British journal of haematology.
2021
Academic Article
GET IT
Times cited: 11 -
The impact of COVID-19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A single-center experience.
European journal of haematology.
2020
Academic Article
GET IT
Times cited: 3 -
Hematopoietic cell transplant outcomes after myeloablative conditioning with fludarabine, busulfan, low-dose total body irradiation, and rabbit antithymocyte globulin.
Clinical transplantation.
2020
Academic Article
GET IT
Times cited: 13 -
The Prognostic Role of Lactate Dehydrogenase at First Relapse of Multiple Myeloma.
Acta haematologica.
2020
Comment
GET IT
Times cited: 10 -
Anti-myeloma potential of ruxolitinib in co-existing JAK2V617F-positive smouldering myeloma and polycythaemia vera.
British journal of haematology.
2020
Letter
GET IT
Times cited: 3 -
Determinants and Prognostic Significance of Serial Right Heart Function Changes in Patients With Cardiac Amyloidosis.
The Canadian journal of cardiology.
2020
Academic Article
GET IT
Times cited: 24 -
High incidence of Pneumocystis jirovecii pneumonia in allogeneic hematopoietic cell transplant recipients in the modern era.
Cytotherapy.
2019
Academic Article
GET IT
Times cited: 27 -
Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for the Treatment of Newly Diagnosed AL Amyloidosis: Impact of Response on Survival Outcomes.
Clinical lymphoma, myeloma & leukemia.
2019
Academic Article
GET IT
Times cited: 11 -
Slow lenalidomide desensitization protocol for patients with multiple myeloma: case series from a single center.
Leukemia & lymphoma.
2019
Academic Article
GET IT
Times cited: 10 -
Antirelapse effect of pretransplant exposure to rabbit antithymocyte globulin.
Blood advances.
2019
Academic Article
GET IT
Times cited: 16 -
Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model.
Blood advances.
2019
Academic Article
GET IT
Times cited: 22 -
Clinical Experience With the Use of Doxycycline and Ursodeoxycholic Acid for the Treatment of Transthyretin Cardiac Amyloidosis.
Journal of cardiac failure.
2019
Academic Article
GET IT
Times cited: 56 -
Bortezomib Maintenance for the Treatment of Monoclonal Gammopathy of Renal Significance.
2019
GET IT
Times cited: 5 -
Epstein-barr virus DNAemia monitoring for the management of post-transplant lymphoproliferative disorder.
Cytotherapy.
2018
Academic Article
GET IT
Times cited: 25 -
Aplastic anemia secondary to nivolumab and ipilimumab in a patient with metastatic melanoma: a case report.
2018
GET IT
Times cited: 28 -
Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transplantation.
Clinical transplantation.
2017
Academic Article
GET IT
Times cited: 26 -
Immunoparesis and polyclonal immunoglobulin recovery after auto-SCT for patients with multiple myeloma treated at a single institution.
Leukemia & lymphoma.
2017
Academic Article
GET IT
Times cited: 18 -
Early Relapse for Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Therapy: A Single-center Experience.
Clinical lymphoma, myeloma & leukemia.
2017
Academic Article
GET IT
Times cited: 10 -
Assessment of renal response with urinary exosomes in patients with AL amyloidosis: A proof of concept.
American journal of hematology.
2017
Academic Article
GET IT
Times cited: 16 -
Acquired von Willebrand Syndrome Associated to Secondary IgM MGUS Emerging after Autologous Stem Cell Transplantation for AL Amyloidosis.
2017
GET IT
Times cited: 3 -
Minimal residual disease (MRD) assessment by flow cytometry after ASCT for AL amyloidosis: are we there yet?.
Bone marrow transplantation.
2017
Academic Article
GET IT
Times cited: 13 -
Bortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myeloma.
Annals of hematology.
2017
Academic Article
GET IT
Times cited: 23 - Zoster prophylaxis after allogeneic hematopoietic cell transplantation using acyclovir/valacyclovir followed by vaccination. Blood advances. 2016 Academic Article GET IT
-
Revised International Staging System Applied to Real World Multiple Myeloma Patients.
Clinical lymphoma, myeloma & leukemia.
2016
Academic Article
GET IT
Times cited: 36 -
Bortezomib-Containing Regimens for the Treatment of Newly Diagnosed and Relapsed Amyloid Light Chain Amyloidosis: A Single-Center Experience.
Clinical lymphoma, myeloma & leukemia.
2016
Academic Article
GET IT
Times cited: 14 -
Bortezomib and melphalan conditioning increases the rate of complete response and MRD negativity for patients with multiple myeloma undergoing single autologous stem cell transplant.
Leukemia & lymphoma.
2015
Letter
GET IT
Times cited: 6 -
Low Counts of B Cells, Natural Killer Cells, Monocytes, Dendritic Cells, Basophils, and Eosinophils are Associated with Postengraftment Infections after Allogeneic Hematopoietic Cell Transplantation.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
2015
Academic Article
GET IT
Times cited: 21 -
Co-existent B-cell and plasma cell neoplasms: a case series providing novel clinical insight.
Leukemia & lymphoma.
2015
Academic Article
GET IT
Times cited: 3 -
Absolute lymphocyte count as predictor of overall survival for patients with multiple myeloma treated with single autologous stem cell transplant.
Leukemia & lymphoma.
2015
Academic Article
GET IT
Times cited: 33 -
A novel transthyretin variant p.H110D (H90D) as a cause of familial amyloid polyneuropathy in a large Irish kindred.
2014
GET IT
Times cited: 5 -
Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma.
British journal of haematology.
2014
Academic Article
GET IT
Times cited: 18 -
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia.
Leukemia & lymphoma.
2014
Letter
GET IT
Times cited: 11 -
Oligoclonal and monoclonal bands after single autologous stem cell transplant in patients with multiple myeloma: impact on overall survival and progression-free survival.
Leukemia & lymphoma.
2014
Academic Article
GET IT
Times cited: 14 -
Leukocyte cell-derived chemotaxin 2 (LECT2)-associated amyloidosis is a frequent cause of hepatic amyloidosis in the United States.
Blood.
2014
Academic Article
GET IT
Times cited: 71 -
Activity of 129 single-agent drugs in 228 phase I and II clinical trials in multiple myeloma.
Clinical lymphoma, myeloma & leukemia.
2013
Review
GET IT
Times cited: 14 -
Autologous stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis: experience of a single institution.
British journal of haematology.
2013
Academic Article
GET IT
Times cited: 21 -
Inhibiting aberrant signal transducer and activator of transcription protein activation with tetrapodal, small molecule Src homology 2 domain binders: promising agents against multiple myeloma.
Journal of medicinal chemistry.
2013
Academic Article
GET IT
Times cited: 40 -
Recurrent chromosome abnormalities define nonoverlapping unique subgroups of tumors in patients with chronic lymphocytic leukemia and known karyotypic abnormalities.
Clinical lymphoma, myeloma & leukemia.
2013
Academic Article
GET IT
Times cited: 3 -
Dissecting karyotypic patterns in non-hyperdiploid multiple myeloma: an overview on the karyotypic evolution.
Clinical lymphoma, myeloma & leukemia.
2013
Academic Article
GET IT
Times cited: 6 -
Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents.
British journal of haematology.
2013
Academic Article
GET IT
Times cited: 102 -
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma.
Leukemia & lymphoma.
2013
Academic Article
GET IT
Times cited: 13 -
AL amyloidosis: an epidemiological and clinical challenge.
Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.
2013
Letter
GET IT
Times cited: 1 -
Autologous stem cell transplant for light chain deposition disease: incorporating bortezomib to the induction therapy.
American journal of hematology.
2012
Academic Article
GET IT
Times cited: 12 -
Light chain deposition disease affecting the gastrointestinal tract in the setting of post-living donor kidney transplantation.
2012
GET IT
Times cited: 8 -
Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis.
Blood.
2012
Academic Article
GET IT
Times cited: 340 -
Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
2011
Academic Article
GET IT
Times cited: 109 -
Monoclonal gammopathy of undetermined significance does not affect outcomes in patients undergoing solid organ transplants.
Transplantation.
2011
Academic Article
GET IT
Times cited: 32 -
Cyclophosphamide and prednisone induction followed by cyclophosphamide mobilization effectively decreases the incidence of engraftment syndrome in patients with POEMS syndrome who undergo stem cell transplantation.
American journal of hematology.
2011
Academic Article
GET IT
Times cited: 20 -
Chromosome abnormalities defined by conventional cytogenetics in plasma cell leukemia: what have we learned about its biology?.
European journal of haematology.
2011
Academic Article
GET IT
Times cited: 16 -
Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia.
Cancer research.
2009
Academic Article
GET IT
Times cited: 142 -
Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis.
International journal of hematology.
2009
Review
GET IT
Times cited: 30